RecruitingNCT03327779

World Bleeding Disorders Registry

Sponsor

World Federation of Hemophilia

Enrollment

20,000 participants

Start Date

Jan 26, 2018

Study Type

OBSERVATIONAL

Conditions

Hemophilia A Hemophilia B Von Willebrand Diseases

Summary

The WBDR is an international observational disease registry of patients with hemophilia. It will provide a platform for a network of hemophilia treatment centres (HTCs) around the world to collect uniform and standardized patient data and guide clinical practice. With informed consent from the patient, the WBDR stores anonymous data about the person's disease, such as hemophilia type and severity, symptoms, and treatment.

Eligibility

Plain Language Summary

Simplified for easier understanding

This global registry collects data on patients with bleeding disorders — specifically Hemophilia A, Hemophilia B, and von Willebrand Disease — treated at participating Hemophilia Treatment Centers worldwide. The aim is to build a large database to improve understanding and care of these conditions. You may be eligible if: - You are a patient at a participating Hemophilia Treatment Centre - You have Hemophilia A, Hemophilia B, or von Willebrand Disease You may NOT be eligible if: - There are no exclusion criteria for this registry Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

World Federation of Hemophilia

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03327779

Related Trials

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

NCT065791448 locations

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

NCT0556871919 locations

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

NCT0593658016 locations

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

NCT0708090511 locations

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

NCT074165262 locations